Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Best Option for Transplant Candidates with Type 1 Diabetes and a Live Kidney Donor: A Bird in the Hand is Worth Two in the Bush

Peter P. Reese and Ajay K. Israni
CJASN April 2009, 4 (4) 700-702; DOI: https://doi.org/10.2215/CJN.00890209
Peter P. Reese
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ajay K. Israni
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading

For patients with type 1 diabetes complicated by ESRD, kidney transplantation prolongs life and frees the recipient from the substantial morbidities of dialysis. Live-donor kidney transplant (LDKT) and simultaneous pancreas-kidney transplant (SPKT) offer distinct benefits over receiving a deceased-donor kidney transplant (DDKT) alone. When a transplant physician is counseling a patient who has type 1 diabetes and ESRD and has a live donor, the decision about whether to proceed with LDKT or to remain on the waiting list for an SPKT requires careful consideration. The retrospective study by Young et al. (1) in this issue of CJASN provides an updated look at posttransplantation outcomes that illustrates the relative advantages of LDKT versus SPKT. Their findings support the adage that a bird in the hand may be worth two in the bush.

The comparison of LDKT and SPKT requires scrutiny of mortality and health-related quality of life, as well as differences in the patients who are candidates for each therapy. The excellent outcomes in patient and allograft survival with LDKT result from minimization of organ ischemia, the ability to optimize recipient health before surgery, and also from overt and subtle differences between those fortunate enough to have a live donor and those who are not. LDKT recipients enjoy decreased rates of delayed graft function, prolonged allograft survival, and longer life compared with DDKT recipients (2). LDKT recipients are often able to undergo transplantation before initiating dialysis (3). Comorbidities such as cardiovascular disease can be carefully treated before the scheduled surgery, which may decrease perioperative morbidity. For all of these reasons, transplant programs have increased the volume of LDKT in the past decade through a variety of methods, including promoting laparoscopic nephrectomy, developing donor exchange programs, and pushing the envelope regarding acceptance of older donors and those with comorbidities such as hypertension (4–7). The exceptional results with LDKT probably also stem from important sociodemographic differences between transplant candidates with a live donor versus those without one. For instance, LDKT recipients are less likely to be black (8) and may also have higher income than patients who receive a DDKT (9). These differences must be kept in mind when evaluating why observed LDKT outcomes are consistently better than those after DDKT.

Successful pancreas transplantation can dramatically improve health-related quality of life by relieving the recipient of the burdens of insulin therapy and the risks for severe hypoglycemic events that accompany erratic glycemic control. Pancreas transplantation may also improve diabetic microvascular complications such as neuropathy (10), but previous studies have not provided consistent evidence that the SPKT approach prolongs life compared with LDKT. For instance, a retrospective cohort study using United Network for Organ Sharing (UNOS) data by Reddy et al. (11) showed no significant difference in mortality among LDKT and SPKT recipients by 8 yr after transplantation (unadjusted survival 72% at 8 yr in each group). A more recent analysis of nonconsecutive LDKT and SPKT recipients whose results were voluntarily reported to the Collaborative Transplant Study reported that patient survival was better for SPKT recipients compared with LDKT recipients only after 10 yr, when analyses were adjusted for baseline cardiovascular risk (hazard ratio 0.55; 95% confidence interval 0.36 to 0.83; P = 0.005). The authors of the Collaborative Transplant Study hypothesized that better life expectancy among SPKT recipients after a decade of follow-up was a result of long-term glycemic control (12).

Eligibility criteria for SPKT must also be examined when comparing results with LDKT and DDKT. Compared with kidney transplant alone, SPKT is associated with a higher rate of morbidities, including cardiac complications, and postoperative infections that candidates must be hardy enough to endure (13,14). Adults considered for SPKT may undergo more extensive cardiovascular screening and may be considered ineligible if significant cardiac or peripheral vascular disease is present (12,15,16). In addition, some transplant centers use recipient age as a criterion for pancreas transplantation to minimize the risk for adverse cardiac events (16,17).

The retrospective study by Young et al. in this issue used data from UNOS to examine posttransplantation outcomes for adult kidney and kidney-pancreas recipients in the United States. Compared with SPKT recipients, LDKT recipients had better death-censored kidney allograft survival (hazard ratio 0.71; 95% confidence interval 0.61 to 0.83; P < 0.001). Because unadjusted mortality curves crossed by 5 yr, however, it is difficult to draw a meaningful conclusion from this study about long-term differences in patient survival between SPKT and LDKT recipients.

For the clinician evaluating transplant options for a candidate with type 1 diabetes and a live kidney donor, this study by Young et al. illuminates the advantage in allograft survival that LDKT recipients enjoy. In considering the circumstances of an individual candidate, the transplant team will need to weigh whether the benefits of better glycemic control favor a pancreas transplant (simultaneously or sequentially). In addition, the team must assess whether the patient's cardiovascular health is adequate and whether the patient is willing to accept the added perioperative risks of pancreas transplant surgery. If the transplant candidate is fortunate enough to have the “bird in the hand” of an appropriate live donor, then LDKT should be pursued. Patients who receive an LDKT can later opt for a sequential pancreas transplant (or in some centers a pancreatic islet transplant). Such decision making requires integration of health-related quality of life, morbidity, and personal preferences, none of which is easily addressed by registry data provided by UNOS.

As kidney and pancreas transplantation research continues to innovate, further studies will be important to match candidates to the best modality. Notably, Young et al. did not examine mortality outcomes for individuals who had type 1 diabetes and remained on the waiting list. A study of mortality from the time of placement of the waiting list for all candidates with type 1 diabetes (rather than just transplant recipients) could provide insight into the cumulative risks of electing to wait for an SPKT compared with opting for an LDKT. In addition, long-term follow-up studies of SPKT recipients that assess the impact of better glycemic control on comorbidities and renal allograft survival will be valuable for better understanding of the range of benefits related to receiving a pancreas transplant. In the meantime, given ever-longer wait times for deceased-donor organs, this new study by Young et al. should encourage patients with type 1 diabetes and a live donor to pursue LDKT.

Disclosures

None.

Acknowledgments

This work was supported by a grant from the Robert Wood Johnson Foundation Physician Faculty Scholar Program (to A.K.I.) and the National Institutes of Health (DK078688-01 to P.P.R.).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Living Donor Kidney Versus Simultaneous Pancreas-Kidney Transplant in Type I Diabetics: An Analysis of the OPTN/UNOS Database,” on pages 845–852.

  • Copyright © 2009 by the American Society of Nephrology

References

  1. ↵
    Young B, Gill J, Huang E, Anastasi B, Takemoto S, Sha T, Bunnapradist, S: Living donor kidney versus simultaneous pancreas-kidney transplant in type I diabetics: An analysis of the OPTN/UNOS database. Clin J Am Soc Nephrol4 :845– 852,2009
    OpenUrlAbstract/FREE Full Text
  2. ↵
    US Renal Data System: Chapter Seven, Transplantation. In: USRDS 2008 Annual Report, Figures 7.23-7.26, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases,2008
  3. ↵
    Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT: Preemptive kidney transplantation: The advantage and the advantaged. J Am Soc Nephrol13 :1358– 1364,2002
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Nanidis TG, Antcliffe D, Kokkinos C, Borysiewicz CA, Darzi AW, Tekkis PP, Papalois VE: Laparoscopic versus open live donor nephrectomy in renal transplantation: A meta-analysis. Ann Surg247 :58– 70,2008
    OpenUrlCrossRefPubMed
  5. Segev DL, Gentry SE, Warren DS, Reeb B, Montgomery RA: Kidney paired donation and optimizing the use of live donor organs. JAMA293 :1883– 1890,2005
    OpenUrlCrossRefPubMed
  6. Textor SC, Taler SJ, Driscoll N, Larson TS, Gloor J, Griffin M, Cosio F, Schwab T, Prieto M, Nyberg S, Ishitani M, Stegall M: Blood pressure and renal function after kidney donation from hypertensive living donors. Transplantation78 :276– 282,2004
    OpenUrlPubMed
  7. ↵
    Gill JS, Gill J, Rose C, Zalunardo N, Landsberg D: The older living kidney donor: Part of the solution to the organ shortage. Transplantation82 :1662– 1666,2006
    OpenUrlCrossRefPubMed
  8. ↵
    United Network for Organ Sharing. Available at: http://www.unos.org/data/data_resources.asp. Accessed January 23,2009
  9. ↵
    Gourlay WA, Stothers L, Liu L: Attitudes and predictive factors for live kidney donation in British Columbia: A comparison of recipients and wait-list patients. Can J Urol12 :2511– 2520,2005
    OpenUrlPubMed
  10. ↵
    Allen RD, Al-Harbi IS, Morris JG, Clouston PD, O'Connell PJ, Chapman JR, Nankivell BJ: Diabetic neuropathy after pancreas transplantation: Determinants of recovery. Transplantation63 :830– 838,1997
    OpenUrlCrossRefPubMed
  11. ↵
    Reddy KS, Stablein D, Taranto S, Stratta RJ, Johnston TD, Waid TH, McKeown JW, Lucas BA, Ranjan D: Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type1 diabetes mellitus and renal failure. Am J Kidney Dis 41 :464– 470,2003
    OpenUrl
  12. ↵
    Morath C, Zeier M, Dohler B, Schmidt J, Nawroth PP, Opelz G: Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol19 :1557– 1563,2008
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Sollinger HW, Odorico JS, Knechtle SJ, D'Alessandro AM, Kalayoglu M, Pirsch JD: Experience with 500 simultaneous pancreas-kidney transplants. Ann Surg228 :284– 296,1998
    OpenUrlCrossRefPubMed
  14. ↵
    Smets YF, van der Pijl JW, van Dissel JT, Ringers J, de Fijter JW, Lemkes HH: Infectious disease complications of simultaneous pancreas kidney transplantation. Nephrol Dial Transplant12 :764– 771,1997
    OpenUrlCrossRefPubMed
  15. ↵
    Sutherland DE, Gruessner RW, Dunn DL, Matas AJ, Humar A, Kandaswamy R, Mauer SM, Kennedy WR, Goetz FC, Robertson RP, Gruessner AC, Najarian JS: Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg233 :463– 501,2001
    OpenUrlCrossRefPubMed
  16. ↵
    Becker BN, Odorico JS, Becker YT, Groshek M, Werwinski C, Pirsch JD, Sollinger HW: Simultaneous pancreas-kidney and pancreas transplantation. J Am Soc Nephrol12 :2517– 2527,2001
    OpenUrlFREE Full Text
  17. ↵
    Robertson RP: Patient selection for an immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus. www.uptodate.com. Accessed February 2,2009 .
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology
Vol. 4, Issue 4
April 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Best Option for Transplant Candidates with Type 1 Diabetes and a Live Kidney Donor: A Bird in the Hand is Worth Two in the Bush
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Best Option for Transplant Candidates with Type 1 Diabetes and a Live Kidney Donor: A Bird in the Hand is Worth Two in the Bush
Peter P. Reese, Ajay K. Israni
CJASN Apr 2009, 4 (4) 700-702; DOI: 10.2215/CJN.00890209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Best Option for Transplant Candidates with Type 1 Diabetes and a Live Kidney Donor: A Bird in the Hand is Worth Two in the Bush
Peter P. Reese, Ajay K. Israni
CJASN Apr 2009, 4 (4) 700-702; DOI: 10.2215/CJN.00890209
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Telehealth and Kidney Disease Care
  • Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy?
  • Should We Let Dialysis Patients Eat Their Fruits and Veggies?
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Living Donor Kidney Versus Simultaneous Pancreas-Kidney Transplant in Type I Diabetics: An Analysis of the OPTN/UNOS Database
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire